Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 1 fiscal years.
-
Busy address KBO
26 other companies have their registered office at the same address; threshold 10.
-
Legal situation KBO
Opening faillissement according to the CBE.
Financials
Financial year 2024
Amalus Therapeutics from Gent, company number BE0803929268, closed financial year 2024 with a result of € -341,736 after tax. For that financial year Amalus Therapeutics recorded a gross margin of € 111,410 and equity of € -331,736. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 7, 2025.
€ -331,736
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -341,736
Profit after tax over the fiscal year.
€ 123,416
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -341,736.
People and assets in 2024
1.6
Average over the fiscal year, from the social balance sheet.
€ 115,359
€ 72,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2024
€ 473,490
Loans from banks and other lenders, long and short.
€ 4,140
Supplier invoices still open on the last day of the fiscal year.
€ 14,158
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
What happened to Amalus Therapeutics?
What happened at Amalus Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
Amalus Therapeutics is active according to the CBE. Legal situation: Opening faillissement.
- New annual accounts for financial year 2024: loss of € 341,736. Source: NBB ↗
- New establishment in Gent. KBO
- Bart Roman became a director. NBB
- Dominic De Groote became a director. NBB
- Christian Stevens became a director. NBB
- Start of the company according to the CBE. KBO
In short
On average € 69,600 of value added per employee in 2024.
A new publication or filing at Amalus Therapeutics? We notify you, reason included.
Follow Amalus TherapeuticsDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Amalus Therapeutics are Bart Roman, Dominic De Groote and Christian Stevens. It owns 100% of Amalus Therapeutics Denmark APS itself.
Directors
According to the 2024 annual accounts
since 2023
since 2023
since 2023
Establishments
Establishment units
Physical locations of this company
Technologiepark-Zwijnaarde 82
9052 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 26 companies are registered at this address.
All companies at this address →CONTREL EUROPE
€ 250,724 gross margin · 2025
INCUBATIE- EN INNOVATIECENTRUM UNIVERSITEIT
€ 1.4 million gross margin · 2025
VP VENTURES
€ -1,670 gross margin · 2025
SENSNET
Inbiose
€ 6.3 million revenue · 2025
+21 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0803.929.268
- VAT number
- BE 0803.929.268
- Registered office
- Technologiepark-Zwijnaarde 82, 9052 Gent
- Names & denominations
- Amalus Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Opening faillissement
- Start date
- 13 July 2023
- Peppol
- Active · Active since 24 Jan 2024
- Activities · NACE
Vervaardiging van farmaceutische grondstoffen
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Vervaardiging van geneesmiddelen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied